ArticleNeurocritical care2026
Ketogenic Diet in Super-Refractory Status Epilepticus: A Retrospective Cohort Study with Severity-Matched Controls in Critically Ill Adults.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ketogenic Diet for Intensive Care Patients: A Scoping Review.Nutrients · 2026Article
- Current concepts on feeding the critically ill patient: a narrative review.Critical care (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSuper-refractory status epilepticus (SRSE) is a life-threatening neurological emergency with limited treatment options. A ketogenic diet (KD) is increasingly considered as a rescue therapy, but controlled data in critically ill adults remain scarce. This study aimed to evaluate the feasibility, safety, and clinical effects of KD in adult SRSE using a severity-matched control group.
methodsA retrospective, severity-matched cohort study compared adult patients with SRSE treated with KD to matched controls. The primary outcome was SRSE resolution. Secondary outcomes included the modified Rankin Scale (mRS) and mortality at 3 and 6 months. Time-dependent and multivariate Cox regression models adjusted for illness severity (including age and Status Epilepticus Severity Score [STESS]) and delayed KD initiation. Despite pragmatic matching, baseline differences in age, STESS, and seizure type were addressed through multivariate adjustment.
resultsA total of 34 adult patients with SRSE were analyzed (18 KD, 16 control). KD was initiated after a mean of 16.6 ± 9.4 days and maintained for 12.9 ± 7.7 days. Ketosis was achieved in 33%, with mild, manageable complications in 28%. SRSE resolution occurred in 61.1% of KD patients vs. 87.5% of controls (p = 0.125), although KD patients had significantly longer status epilepticus duration and higher medication burden. Time-dependent Cox regression showed an association with faster SRSE resolution after KD initiation (hazard ratio [HR] 0.26, 95% confidence interval [CI] 0.07-0.97; p = 0.045). In the multivariate Cox model, KD remained independently associated with SRSE resolution (HR 0.368, 95% CI 0.176-0.756; p = 0.006). Earlier KD initiation was independently associated with improved seizure control (p = 0.015). At 3 and 6 months, KD patients showed significantly better functional outcomes (p = 0.023 and p = 0.021, respectively). Ketosis or ketone levels were not associated with outcome, suggesting that therapeutic effects may be independent of measurable ketosis.
conclusionsKD is feasible and safe in adult patients with SRSE. Time-dependent models showed a significant therapeutic association, particularly with earlier initiation. These findings support prospective evaluation of KD as a nonpharmacologic therapy in neurocritical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.